Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
Zydus MedTech, a wholly owned subsidiary of Zydus Lifesciences, specialising in medical technology development, has entered into a strategic partnership with Braile Biomédica Indústria, Comércio e Representações Ltda., (Braile Biomedica) – an innovative cardiovascular device manufacturer based in Brazil – to exclusively commercialise its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets.
Zydus MedTech, is actively building its interventional cardiology portfolio, will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets, leveraging its commercial and regulatory expertise. Braile Biomedica – with a proven track record in cardiovascular innovation, particularly in Latin America – will manufacture and supply the product for these markets.
Zydus MedTech will also retain rights to manufacture select components of the TAVI system. This collaboration provides operational flexibility while laying the foundation for further product innovation and development.
The agreement aligns with both companies’ shared commitment to delivering life-saving technologies to a broader patient population. The TAVI procedure is a recognised breakthrough in structural heart care, particularly for elderly patients or those at high surgical risk. By replacing the diseased aortic valve through a catheter-based approach – without the need for open-heart surgery – patients often experience significantly shorter recovery times and reduced procedural risks. The expansion of TAVI indications to all-risk patients has further accelerated its adoption.
Dr Sharvil Patel, MD, Zydus Lifesciences, said “We stand united with Braile to improve patient outcomes and expand access to advanced, critical cardiovascular care globally. The innovative, cutting-edge technology will offer a minimally invasive approach that also supports faster recovery, reduced hospital stays, and greatly improved quality of life for patients.”
Patricia Braile, CEO, Braile Biomedica, said, “The partnership with Zydus MedTech powerfully reinforces Braile’s mission to care for people and help save lives. Seeing our TAVI technology — the result of decades of dedication to cardiovascular innovation — reach new continents is the fulfilment of a purpose that has driven us for nearly fifty years. By joining forces with a partner that shares our values and commitment, we expand our global impact and bring hope and quality of life to even more patients around the world.”
